# Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

> **NCT06911320** · PHASE1 · RECRUITING · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Healthy Volunteer Study
- Hepatic Impairment
- Renal Impairment

## Interventions

- **DRUG:** Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

## Key facts

- **NCT ID:** NCT06911320
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911320, "Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06911320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*